Oruka Therapeutics, Inc.
Income Statement
| Line Item | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $3.1M | — | — | — | — | — | — |
| SG&A Expense | $6.1M | — | — | — | — | — | — |
| Operating Income | $-9.2M | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | $8.0K | — | — | — | — | — | — |
| Pretax Income | $-8.4M | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | $-8.4M | $-9.1M | $-19.4M | $-14.0M | $-5.2M | $-1.5M | $-511.0K |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.12 | — | — | — | — | — | — |
| EPS (Diluted) | $-0.12 | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 70.7M | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | 70.7M | — | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — | — | — |